Celgene Partners With Acceleron On Novel Bone Forming Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
$997 million deal will includes ACE-011 for cancer-related bone loss and other discovery compounds.
You may also be interested in...
Financings Of The Fortnight Hopes 2011 Didn’t Set A (Low) Fundraising Benchmark For 2012
Plus news on recent financings by Warp Drive Bio, Synageva BioPharma, Elevation Pharmaceuticals and Acceleron Pharma.
Acceleron And Celgene Expand Anemia Collaboration With Second Compound
The two companies will split development costs for ACE-536 in anemia-related conditions, and Acceleron will hold North American co-promotion rights.
Acceleron And Celgene Expand Anemia Collaboration With Second Compound
The two companies will split development costs for ACE-536 in anemia-related conditions, and Acceleron will hold North American co-promotion rights.